Shandong Realcan Pharmaceutical Co Ltd (002589) - Net Assets
Based on the latest financial reports, Shandong Realcan Pharmaceutical Co Ltd (002589) has net assets worth CN¥5.45 Billion CNY (≈ $798.12 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥15.33 Billion ≈ $2.24 Billion USD) and total liabilities (CN¥9.87 Billion ≈ $1.44 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Shandong Realcan Pharmaceutical Co Ltd liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥5.45 Billion |
| % of Total Assets | 35.58% |
| Annual Growth Rate | 27.84% |
| 5-Year Change | -40.94% |
| 10-Year Change | 67.27% |
| Growth Volatility | 56.93 |
Shandong Realcan Pharmaceutical Co Ltd - Net Assets Trend (2008–2024)
This chart illustrates how Shandong Realcan Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore 002589 asset base for the complete picture of this company's asset base.
Annual Net Assets for Shandong Realcan Pharmaceutical Co Ltd (2008–2024)
The table below shows the annual net assets of Shandong Realcan Pharmaceutical Co Ltd from 2008 to 2024. For live valuation and market cap data, see 002589 market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥5.69 Billion ≈ $833.30 Million |
+1.02% |
| 2023-12-31 | CN¥5.64 Billion ≈ $824.87 Million |
-2.00% |
| 2022-12-31 | CN¥5.75 Billion ≈ $841.67 Million |
-40.66% |
| 2021-12-31 | CN¥9.69 Billion ≈ $1.42 Billion |
+0.53% |
| 2020-12-31 | CN¥9.64 Billion ≈ $1.41 Billion |
-5.95% |
| 2019-12-31 | CN¥10.25 Billion ≈ $1.50 Billion |
-9.32% |
| 2018-12-31 | CN¥11.31 Billion ≈ $1.65 Billion |
+16.87% |
| 2017-12-31 | CN¥9.67 Billion ≈ $1.42 Billion |
+28.95% |
| 2016-12-31 | CN¥7.50 Billion ≈ $1.10 Billion |
+120.38% |
| 2015-12-31 | CN¥3.40 Billion ≈ $498.16 Million |
+86.51% |
| 2014-12-31 | CN¥1.83 Billion ≈ $267.10 Million |
+10.63% |
| 2013-12-31 | CN¥1.65 Billion ≈ $241.45 Million |
+80.05% |
| 2012-12-31 | CN¥916.39 Million ≈ $134.10 Million |
+12.15% |
| 2011-12-31 | CN¥817.11 Million ≈ $119.57 Million |
+176.02% |
| 2010-12-31 | CN¥296.03 Million ≈ $43.32 Million |
+26.41% |
| 2009-12-31 | CN¥234.18 Million ≈ $34.27 Million |
+109.30% |
| 2008-12-31 | CN¥111.89 Million ≈ $16.37 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Shandong Realcan Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 570.7% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥276.99 Million | 5.00% |
| Common Stock | CN¥1.50 Billion | 27.17% |
| Other Components | CN¥3.76 Billion | 67.83% |
| Total Equity | CN¥5.54 Billion | 100.00% |
Shandong Realcan Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Shandong Realcan Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Kingfa Science & Technology (India) Limited
NSE:KINGFA
|
$700.39 Million |
|
PSI Software AG
F:PSAN
|
$700.76 Million |
|
Citycon Oyj
HE:CTY1S
|
$700.87 Million |
|
Beijing Career International Co Ltd
SHE:300662
|
$700.97 Million |
|
Materials Analysis Technology
TWO:3587
|
$700.15 Million |
|
Beijing Bayi Space LCD Technology Co Ltd
SHG:688181
|
$699.98 Million |
|
CSB Bank Limited
NSE:CSBBANK
|
$699.76 Million |
|
Collins Foods Ltd
AU:CKF
|
$699.64 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shandong Realcan Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 5,447,794,000 to 5,537,792,000, a change of 89,998,000 (1.7%).
- Net income of 20,622,000 contributed positively to equity growth.
- Dividend payments of 198,706,000 reduced retained earnings.
- Share repurchases of 33,337,891 reduced equity.
- Other comprehensive income decreased equity by 257,432,000.
- Other factors increased equity by 558,851,891.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥20.62 Million | +0.37% |
| Dividends Paid | CN¥198.71 Million | -3.59% |
| Share Repurchases | CN¥33.34 Million | -0.6% |
| Other Comprehensive Income | CN¥-257.43 Million | -4.65% |
| Other Changes | CN¥558.85 Million | +10.09% |
| Total Change | CN¥- | 1.65% |
Book Value vs Market Value Analysis
This analysis compares Shandong Realcan Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.86x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 13.87x to 0.86x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-12-31 | CN¥0.23 | CN¥3.18 | x |
| 2009-12-31 | CN¥0.40 | CN¥3.18 | x |
| 2010-12-31 | CN¥0.46 | CN¥3.18 | x |
| 2011-12-31 | CN¥1.09 | CN¥3.18 | x |
| 2012-12-31 | CN¥1.06 | CN¥3.18 | x |
| 2013-12-31 | CN¥1.85 | CN¥3.18 | x |
| 2014-12-31 | CN¥1.81 | CN¥3.18 | x |
| 2015-12-31 | CN¥2.59 | CN¥3.18 | x |
| 2016-12-31 | CN¥5.09 | CN¥3.18 | x |
| 2017-12-31 | CN¥5.19 | CN¥3.18 | x |
| 2018-12-31 | CN¥5.70 | CN¥3.18 | x |
| 2019-12-31 | CN¥4.80 | CN¥3.18 | x |
| 2020-12-31 | CN¥5.15 | CN¥3.18 | x |
| 2021-12-31 | CN¥5.19 | CN¥3.18 | x |
| 2022-12-31 | CN¥3.67 | CN¥3.18 | x |
| 2023-12-31 | CN¥3.62 | CN¥3.18 | x |
| 2024-12-31 | CN¥3.68 | CN¥3.18 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shandong Realcan Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.37%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.26%
- • Asset Turnover: 0.50x
- • Equity Multiplier: 2.89x
- Recent ROE (0.37%) is below the historical average (6.16%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | 26.08% | 2.54% | 1.60x | 6.39x | CN¥17.99 Million |
| 2009 | 19.13% | 2.79% | 1.54x | 4.45x | CN¥21.37 Million |
| 2010 | 20.98% | 2.81% | 1.50x | 5.00x | CN¥32.51 Million |
| 2011 | 10.31% | 2.63% | 1.44x | 2.72x | CN¥2.54 Million |
| 2012 | 12.07% | 2.39% | 1.48x | 3.40x | CN¥19.01 Million |
| 2013 | 8.80% | 2.42% | 1.33x | 2.73x | CN¥-19.61 Million |
| 2014 | 10.07% | 2.32% | 1.37x | 3.16x | CN¥1.20 Million |
| 2015 | 7.39% | 2.42% | 1.10x | 2.77x | CN¥-83.50 Million |
| 2016 | 8.59% | 3.78% | 1.00x | 2.28x | CN¥-96.80 Million |
| 2017 | 12.92% | 4.33% | 0.86x | 3.46x | CN¥227.62 Million |
| 2018 | 9.12% | 2.27% | 0.97x | 4.12x | CN¥-73.95 Million |
| 2019 | -12.91% | -2.63% | 1.09x | 4.52x | CN¥-1.65 Billion |
| 2020 | 3.50% | 0.96% | 0.87x | 4.19x | CN¥-485.60 Million |
| 2021 | 1.73% | 0.62% | 0.80x | 3.49x | CN¥-625.53 Million |
| 2022 | -33.86% | -14.87% | 0.67x | 3.39x | CN¥-2.37 Billion |
| 2023 | 0.37% | 0.25% | 0.48x | 3.07x | CN¥-524.46 Million |
| 2024 | 0.37% | 0.26% | 0.50x | 2.89x | CN¥-533.16 Million |
Industry Comparison
This section compares Shandong Realcan Pharmaceutical Co Ltd's net assets metrics with peer companies in the Medical Distribution industry.
Industry Context
- Industry: Medical Distribution
- Average net assets among peers: $10,654,715,645
- Average return on equity (ROE) among peers: 11.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shandong Realcan Pharmaceutical Co Ltd (002589) | CN¥5.45 Billion | 26.08% | 1.81x | $700.19 Million |
| China National Accord Medicines Corp Ltd (000028) | $8.91 Billion | 13.31% | 1.39x | $1.74 Billion |
| Shenzhen Glory Medical Co Ltd (002551) | $2.82 Billion | 2.12% | 0.68x | $442.93 Million |
| China National Accord Medicines Corp Ltd (200028) | $357.13 Million | 11.35% | 0.25x | $126.15 Million |
| Qingdao Baheal Medical INC. (301015) | $2.60 Billion | 26.55% | 1.73x | $1.90 Billion |
| China Meheco Co Ltd (600056) | $1.54 Billion | 15.23% | 0.77x | $2.27 Billion |
| Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd (600332) | $33.64 Billion | 11.79% | 1.22x | $4.66 Billion |
| China National Medicines Corp Ltd (600511) | $399.62 Million | 6.55% | 1.02x | $3.16 Billion |
| Liaoning Cheng Da Co Ltd (600739) | $20.00 Billion | 4.74% | 0.66x | $2.66 Billion |
| Jointown Pharmaceutical Group Co Ltd (600998) | $25.62 Billion | 12.00% | 2.16x | $3.81 Billion |
About Shandong Realcan Pharmaceutical Co Ltd
Realcan Pharmaceutical Group Co., Ltd. sells medicines, medical devices, and medical consumables to medical institutions in China. It operates through the Drug and Equipment Distribution, In Vitro Diagnostics, Pharmaceutical Logistics, Traditional Chinese Medicine, and Microbiome Medicine segments. The company engages in the processing, manufacture, sale, and wholesale of Chinese medicinal materi… Read more